TY - JOUR AU - Kollár, Levente AU - Grabrijan, Katarina AU - Hrast Rambaher, Martina AU - Bozovičar, Krištof AU - Imre, Tímea AU - Ferenczy, György AU - Gobec, Stanislav AU - Keserű, György Miklós TI - Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents JF - JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY J2 - J ENZYM INHIB MED CH VL - 39 PY - 2024 IS - 1 SN - 1475-6366 DO - 10.1080/14756366.2024.2305833 UR - https://m2.mtmt.hu/api/publication/34718013 ID - 34718013 N1 - Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Hungary Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest, Hungary Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia MS Metabolomics Research Group, Research Centre for Natural Sciences, Budapest, Hungary Export Date: 8 March 2024 CODEN: JEIMA Correspondence Address: Keserű, G.M.; Department of Organic Chemistry and Technology, Műegyetem rkp. 3., Hungary; email: keseru.gyorgy@ttk.hu Funding details: RRF-2.3.1-21-2022-00015 Funding details: Javna Agencija za Raziskovalno Dejavnost RS, ARRS, N1-0169, P1-0208 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFI, K135335 Funding details: Richter Gedeon Talentum Alapítvány Funding text 1: We thank Dr. Andrea Dessen (IBS, Grenoble) for donation of PBP1b plasmid and Dr. Pál Szabó for HRMS measurements. This study was supported by National Research, Development and Innovation Office Grants K135335, and by the National Drug Research and Development Laboratory (PharmaLab) project (RRF-2.3.1-21-2022-00015). Funding text 2: This research was funded by the National Research Development and Innovation Office (Grant Numbers: SNN 135335), Slovenian Research Agency (ARRS) Research Core Funding P1-0208, grant N1-0169 and a PhD grant to K.G. L.K. is supported by the Gedeon Richter Talentum Foundation and the József Varga Foundation and Javna Agencija za Raziskovalno Dejavnost RS. We thank Dr. Andrea Dessen (IBS, Grenoble) for donation of PBP1b plasmid and Dr. Pál Szabó for HRMS measurements. This study was supported by National Research, Development and Innovation Office Grants K135335, and by the National Drug Research and Development Laboratory (PharmaLab) project (RRF-2.3.1-21-2022-00015). LA - English DB - MTMT ER - TY - CHAP AU - Mihalovits, Levente Márk AU - Ferenczy, György AU - Keserű, György Miklós ED - Ramaswamy, Vijayan ED - Poongavanam, Vasanthanathan TI - Free Energy Calculations in Covalent Drug Design T2 - Computational Drug Discovery PB - Wiley SN - 9783527840748 PY - 2024 SP - 561 EP - 578 PG - 18 DO - 10.1002/9783527840748.ch23 UR - https://m2.mtmt.hu/api/publication/34535308 ID - 34535308 LA - English DB - MTMT ER - TY - JOUR AU - Mihalovits, Levente Márk AU - Kollár, Levente AU - Bajusz, Dávid AU - Knez, Damijan AU - Bozovičar, Krištof AU - Imre, Timea AU - Ferenczy, György AU - Gobec, Stanislav AU - Keserű, György Miklós TI - Molecular Mechanism of Labelling Functional Cysteines by Heterocyclic Thiones JF - CHEMPHYSCHEM: A EUROPEAN JOURNAL OF CHEMICAL PHYSICS AND PHYSICAL CHEMISTRY J2 - CHEMPHYSCHEM VL - 25 PY - 2024 IS - 1 SN - 1439-4235 DO - 10.1002/cphc.202300596 UR - https://m2.mtmt.hu/api/publication/34223252 ID - 34223252 N1 - Medicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3., Budapest, 1111, Hungary Department of Medicinal Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana, 1000, Slovenia Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana, 1000, Slovenia MS Metabolomics Research Group, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary Export Date: 24 November 2023 CODEN: CPCHF Correspondence Address: Bajusz, D.; Medicinal Chemistry Research Group, Magyar tudósok krt. 2, Hungary; email: bajusz.david@ttk.hu Correspondence Address: Keserű, G.M.; Medicinal Chemistry Research Group, Magyar tudósok krt. 2, Hungary; email: keseru.gyorgy@ttk.hu AB - Heterocyclic thiones have recently been identified as reversible covalent warheads, consistent with their mild electrophilic nature. Little is known so far about their mechanism of action in labelling nucleophilic sidechains, especially cysteines. The vast number of tractable cysteines promotes a wide range of target proteins to examine; however, our focus was put on functional cysteines. We chose the main protease of SARS‐CoV‐2 harboring Cys145 at the active site that is a structurally characterized and clinically validated target of covalent inhibitors. We screened an in‐house, cysteine‐targeting covalent inhibitor library which resulted in several covalent fragment hits with benzoxazole, benzothiazole and benzimidazole cores. Thione derivatives and Michael acceptors were selected for further investigations with the objective of exploring the mechanism of inhibition of the thiones and using the thoroughly characterized Michael acceptors for benchmarking our studies. Classical and hybrid quantum mechanical/molecular mechanical (QM/MM) molecular dynamics simulations were carried out that revealed a new mechanism of covalent cysteine labelling by thione derivatives, which was supported by QM and free energy calculations and by a wide range of experimental results. Our study shows that the molecular recognition step plays a crucial role in the overall binding of both sets of molecules. LA - English DB - MTMT ER - TY - JOUR AU - Ábrányi-Balogh, Péter AU - Keeley, Aaron AU - Ferenczy, György AU - Petri, László AU - Imre, Timea AU - Grabrijan, Katarina AU - Hrast, Martina AU - Knez, Damijan AU - Ilaš, Janez AU - Gobec, Stanislav AU - Keserű, György Miklós TI - Next-Generation Heterocyclic Electrophiles as Small-Molecule Covalent MurA Inhibitors JF - PHARMACEUTICALS J2 - PHARMACEUTICALS-BASE VL - 15 PY - 2022 IS - 12 SN - 1424-8247 DO - 10.3390/ph15121484 UR - https://m2.mtmt.hu/api/publication/33298396 ID - 33298396 AB - Heterocyclic electrophiles as small covalent fragments showed promising inhibitory activity on the antibacterial target MurA (UDP-N-acetylglucosamine 1-carboxyvinyltransferase, EC:2.5.1.7). Here, we report the second generation of heterocyclic electrophiles: the quaternized analogue of the heterocyclic covalent fragment library with improved reactivity and MurA inhibitory potency. Quantum chemical reaction barrier calculations, GSH (L-glutathione) reactivity assay, and thrombin counter screen were also used to demonstrate and explain the improved reactivity and selectivity of the N-methylated heterocycles and to compare the two generations of heterocyclic electrophiles. LA - English DB - MTMT ER - TY - JOUR AU - Ferenczy, György AU - Kellermayer, Miklós TI - Contribution of hydrophobic interactions to protein mechanical stability JF - COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL J2 - CSBJ VL - 20 PY - 2022 SP - 1946 EP - 1956 PG - 11 SN - 2001-0370 DO - 10.1016/j.csbj.2022.04.025 UR - https://m2.mtmt.hu/api/publication/32830244 ID - 32830244 LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Dóra Judit AU - Oláh, Julianna AU - Tóth, Gergely János AU - Varga, Máté AU - Stirling, András AU - Karancsiné Menyhárd, Dóra AU - Ferenczy, György TI - The Structure-Derived Mechanism of Box H/ACA Pseudouridine Synthase Offers a Plausible Paradigm for Programmable RNA Editing JF - ACS CATALYSIS J2 - ACS CATAL VL - 12 PY - 2022 IS - 5 SP - 2756 EP - 2769 PG - 14 SN - 2155-5435 DO - 10.1021/acscatal.1c04870 UR - https://m2.mtmt.hu/api/publication/32668322 ID - 32668322 N1 - Export Date: 11 October 2022 CODEN: ACCAC Correspondence Address: Menyhárd, D.K.; MTA-ELTE Protein Modelling Research Group, Pázmány P. stny. 1/a, Hungary; email: dora.k.menyhard@ttk.elte.hu Correspondence Address: Ferenczy, G.G.; Medicinal Chemistry Research Group, Magyar tudósok krt. 2, Hungary; email: ferenczy.gyorgy@ttk.hu LA - English DB - MTMT ER - TY - JOUR AU - Mihalovits, Levente Márk AU - Ferenczy, György AU - Keserű, György Miklós TI - The role of quantum chemistry in covalent inhibitor design JF - INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY J2 - INT J QUANTUM CHEM VL - 122 PY - 2022 IS - 8 PG - 17 SN - 0020-7608 DO - 10.1002/qua.26768 UR - https://m2.mtmt.hu/api/publication/32298744 ID - 32298744 N1 - Funding Agency and Grant Number: Nemzeti Kutatasi Fejlesztesi es Innovacios HivatalNational Research, Development & Innovation Office (NRDIO) - Hungary [SNN 125496, SNN 135335] Funding text: Nemzeti Kutatasi Fejlesztesi es Innovacios Hivatal, Grant/Award Numbers: SNN 125496, SNN 135335 AB - The recent ascent of targeted covalent inhibitors (TCI) in drug discovery brings new opportunities and challenges to quantum chemical reactivity calculations supporting discovery efforts. TCIs typically form a covalent bond with the targeted nucleophilic amino acid side chain. Their reactivity that can be both computed and experimentally measured is therefore one of the key factors in determining inhibitory potency. Calculation of relevant quantum chemical descriptors and corresponding reaction barriers of model reactions represent efficient ways to predict intrinsic reactivities of covalent ligands. A more comprehensive description of covalent ligand binding is offered by mixed quantum mechanical/molecular mechanical (QM/MM) potentials. Reaction mechanisms can be investigated by the exploration of the potential energy surface as a function of suitable reaction coordinates, and free energy surfaces can also be calculated with molecular dynamics based simulations. Here we review the methodological aspects and discuss applications with primary focus on high-end QM/MM simulations to illustrate the current status of quantum chemical support to covalent inhibitor design. Available QM approaches are suitable to identify likely reaction mechanisms and rate determining steps in the binding of covalent inhibitors. The efficient QM/MM prediction of ligand reactivities complemented with the computational description of the recognition step makes these computations highly useful in covalent drug discovery. LA - English DB - MTMT ER - TY - JOUR AU - Mihalovits, Levente Márk AU - Ferenczy, György AU - Keserű, György Miklós TI - A kovalens enziminhibíció számításos kémiai jellemzése JF - MAGYAR KÉMIAI FOLYÓIRAT - KÉMIAI KÖZLEMÉNYEK (1997-) J2 - MAGY KÉM FOLY KÉM KÖZL VL - 128 PY - 2022 IS - 3-4 SP - 150 EP - 156 PG - 7 SN - 1418-9933 DO - 10.24100/MKF.2022.03-4.150 UR - https://m2.mtmt.hu/api/publication/33543903 ID - 33543903 N1 - "Mihalovits Levente Márk Computational characterization of covalent enzyme inhibition című PhD értekezéséhez kapcsolódó tézisfüzet alapján készült." LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kollár, Levente AU - Gobec, Martina AU - Proj, Matic AU - Smrdel, Lara AU - Knez, Damijan AU - Imre, Timea AU - Gömöry, Ágnes AU - Petri, László AU - Ábrányi-Balogh, Péter AU - Csányi, Dorottya AU - Ferenczy, György AU - Gobec, Stanislav AU - Sosič, Izidor AU - Keserű, György Miklós TI - Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads JF - CELLS J2 - CELLS-BASEL VL - 10 PY - 2021 IS - 12 PG - 19 SN - 2073-4409 DO - 10.3390/cells10123431 UR - https://m2.mtmt.hu/api/publication/32544488 ID - 32544488 N1 - Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, H-1117, Hungary Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana, SI-1000, Slovenia MS Metabolomics Research Group, Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, H-1117, Hungary MS Proteomics Research Group, Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, H-1117, Hungary Export Date: 27 May 2022 Correspondence Address: Sosič, I.; Faculty of Pharmacy, Aškerčeva cesta 7, Slovenia; email: izidor.sosic@ffa.uni-lj.si Correspondence Address: Keserű, G.M.; Medicinal Chemistry Research Group, Magyar tudósok krt. 2, Hungary; email: keseru.gyorgy@ttk.hu LA - English DB - MTMT ER - TY - JOUR AU - Kollár, Levente AU - Ferenczy, György AU - Proj, Matic AU - Gobec, Martina AU - Gobec, Stanislav AU - Sosič, Izidor AU - Keserű, György Miklós TI - Virtual Screening and Biochemical Testing of Borocycles as Immunoproteasome Inhibitors JF - PERIODICA POLYTECHNICA-CHEMICAL ENGINEERING J2 - PERIOD POLYTECH CHEM ENG VL - 65 PY - 2021 IS - 3 SP - 292 EP - 298 PG - 7 SN - 0324-5853 DO - 10.3311/PPch.17202 UR - https://m2.mtmt.hu/api/publication/32129052 ID - 32129052 LA - English DB - MTMT ER - TY - JOUR AU - Kollár, Levente AU - Gobec, Martina AU - Szilágyi, Bence AU - Proj, Matic AU - Knez, Damijan AU - Ábrányi-Balogh, Péter AU - Petri, László AU - Imre, Timea AU - Bajusz, Dávid AU - Ferenczy, György AU - Gobec, Stanislav AU - Keserű, György Miklós AU - Sosič, Izidor TI - Discovery of selective fragment-sized immunoproteasome inhibitors JF - EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY J2 - EUR J MED CHEM VL - 219 PY - 2021 PG - 23 SN - 0223-5234 DO - 10.1016/j.ejmech.2021.113455 UR - https://m2.mtmt.hu/api/publication/31984014 ID - 31984014 LA - English DB - MTMT ER - TY - JOUR AU - Mihalovits, Levente Márk AU - Ferenczy, György AU - Keserű, György Miklós TI - Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors JF - COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL J2 - CSBJ VL - 19 PY - 2021 SP - 4486 EP - 4496 PG - 11 SN - 2001-0370 DO - 10.1016/j.csbj.2021.08.008 UR - https://m2.mtmt.hu/api/publication/32298742 ID - 32298742 AB - The ubiquitin-proteasome system is responsible for the degradation of proteins and plays a critical role in key cellular processes. While the constitutive proteasome (cPS) is expressed in all eukaryotic cells, the immunoproteasome (iPS) is primarily induced during disease processes, and its inhibition is beneficial in the treatment of cancer, autoimmune disorders and neurodegenerative diseases. Oxathiazolones were reported to selectively inhibit iPS over cPS, and the inhibitory activity of several oxathiazolones against iPS was experimentally determined. However, the detailed mechanism of the chemical reaction leading to irreversible iPS inhibition and the key selectivity drivers are unknown, and separate characterization of the noncovalent and covalent inhibition steps is not available for several compounds. Here, we investigate the chemical reaction between oxathiazolones and the Thr1 residue of iPS by quantum mechanics/ molecular mechanics (QM/MM) simulations to establish a plausible reaction mechanism and to determine the rate-determining step of covalent complex formation. The modelled binding mode and reaction mechanism are in line with the selective inhibition of iPS versus cPS by oxathiazolones. The k(inact )value of several ligands was estimated by constructing the potential of mean force of the rate-determining step by QM/MM simulations coupled with umbrella sampling. The equilibrium constant K-i of the noncovalent complex formation was evaluated by classical force field-based thermodynamic integration. The calculated K-i and kinact values made it possible to analyse the contribution of the noncovalent and covalent steps to the overall inhibitory activity. Compounds with similar intrinsic reactivities exhibit varying selectivities for iPS versus cPS owing to subtle differences in the binding modes that slightly affect K-i, the noncovalent affinity, and importantly alter k(inact), the covalent reactivity of the bound compounds. A detailed understanding of the inhibitory mechanism of oxathiazolones is useful in designing iPS selective inhibitors with improved drug-like properties. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. LA - English DB - MTMT ER - TY - JOUR AU - Orgován, Zoltán AU - Ferenczy, György AU - Keserű, György Miklós TI - Allosteric Molecular Switches in Metabotropic Glutamate Receptors JF - CHEMMEDCHEM J2 - CHEMMEDCHEM VL - 16 PY - 2021 IS - 1 SP - 81 EP - 93 PG - 14 SN - 1860-7179 DO - 10.1002/cmdc.202000444 UR - https://m2.mtmt.hu/api/publication/31698584 ID - 31698584 AB - Metabotropic glutamate receptors (mGlu) are class C G protein-coupled receptors of eight subtypes that are omnipresently expressed in the central nervous system. mGlus have relevance in several psychiatric and neurological disorders, therefore they raise considerable interest as drug targets. Allosteric modulators of mGlus offer advantages over orthosteric ligands owing to their increased potential to achieve subtype selectivity, and this has prompted discovery programs that have produced a large number of reported allosteric mGlu ligands. However, the optimization of allosteric ligands into drug candidates has proved to be challenging owing to induced-fit effects, flat or steep structure-activity relationships and unexpected changes in theirpharmacology. Subtle structural changes identified as molecular switches might modulate the functional activity of allosteric ligands. Here we review these switches discovered in the metabotropic glutamate receptor family.. LA - English DB - MTMT ER - TY - JOUR AU - Scarpino, Andrea AU - Ferenczy, György AU - Keserű, György Miklós TI - Binding Mode Prediction and Virtual Screening Applications by Covalent Docking JF - METHODS IN MOLECULAR BIOLOGY J2 - METHODS MOL BIOL VL - 2266 PY - 2021 SP - 73 EP - 88 PG - 16 SN - 1064-3745 DO - 10.1007/978-1-0716-1209-5_4 UR - https://m2.mtmt.hu/api/publication/31997741 ID - 31997741 N1 - Cited By :2 Export Date: 21 February 2023 Correspondence Address: Keserű, G.M.; Medicinal Chemistry Research Group, Hungary; email: keseru.gyorgy@ttk.hu Chemicals/CAS: protein, 67254-75-5; protein p21, 85306-28-1; KRAS protein, human; Ligands; Proteins; Proto-Oncogene Proteins p21(ras) Funding details: H2020 Marie Skłodowska-Curie Actions, MSCA Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, SNN_17 125496 Funding text 1: The research was supported by the Marie Sklodowska Curie Action (MSCA) Innovative Training Network grant FRAGNET and by the National Research Development and Innovation Office (grant number SNN_17 125496). AB - The mechanism of action of covalent drugs involves the formation of a bond between their electrophilic warhead group and a nucleophilic residue of the protein target. The recent advances in covalent drug discovery have accelerated the development of computational tools for the design and characterization of covalent binders. Covalent docking algorithms can predict the binding mode of covalent ligands by modeling the bonds and interactions formed at the reaction site. Their scoring functions can estimate the relative binding affinity of ligands towards the target of interest, thus allowing virtual screening of compound libraries. However, most of the scoring schemes have no specific terms for the bond formation, and therefore it prevents the direct comparison of warheads with different intrinsic reactivity. Herein, we describe a protocol for the binding mode prediction of covalent ligands, a typical virtual screening of compound sets with a single warhead chemistry, and an alternative approach to screen libraries that include various warhead types, as applied in recently validated studies. © 2021, Springer Science+Business Media, LLC, part of Springer Nature. LA - English DB - MTMT ER - TY - JOUR AU - Scarpino, Andrea AU - Petri, László AU - Knez, Damijan AU - Imre, Timea AU - Ábrányi-Balogh, Péter AU - Ferenczy, György AU - Gobec, Stanislav AU - Keserű, György Miklós TI - WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors JF - JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN J2 - J COMPUT AID MOL DES VL - 35 PY - 2021 IS - 2 SP - 223 EP - 244 PG - 22 SN - 0920-654X DO - 10.1007/s10822-020-00371-5 UR - https://m2.mtmt.hu/api/publication/31848994 ID - 31848994 N1 - Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt 2, Budapest, 1117, Hungary Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, Ljubljana, 1000, Slovenia MS Metabolomic Research Laboratory, Research Centre for Natural Sciences, Magyar tudósok krt 2, Budapest, 1117, Hungary Export Date: 3 March 2021 CODEN: JCADE Correspondence Address: Keserű, G.M.; Medicinal Chemistry Research Group, Magyar tudósok krt 2, Hungary; email: keseru.gyorgy@ttk.hu Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt 2, Budapest, 1117, Hungary Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, Ljubljana, 1000, Slovenia MS Metabolomic Research Laboratory, Research Centre for Natural Sciences, Magyar tudósok krt 2, Budapest, 1117, Hungary Export Date: 4 March 2021 CODEN: JCADE Correspondence Address: Keserű, G.M.; Medicinal Chemistry Research Group, Magyar tudósok krt 2, Hungary; email: keseru.gyorgy@ttk.hu Funding details: Marie Curie Funding details: Javna Agencija za Raziskovalno Dejavnost RS, ARRS, L1-8157, P1-0208, Z1-1859 Funding details: National Research, Development and Innovation Office, 2017-1.2.1-NKP-2017-00002, K111862, PD124598 Funding text 1: Open Access funding provided by ELKH Research Centre for Natural Sciences. This work has been supported by the Marie Sklodowska Curie Action (MSCA) Innovative Training Network grant FRAGNET, by the National Office for Research, Development and Innovation (2017-1.2.1-NKP-2017-00002, K111862 and PD124598 Grants), and by Slovenian Research Agency—ARRS (Grants Z1-1859, P1-0208 and L1-8157). LA - English DB - MTMT ER - TY - JOUR AU - Ferenczy, György AU - Keserű, György Miklós TI - Thermodynamic profiling for fragment-based lead discovery and optimization JF - EXPERT OPINION ON DRUG DISCOVERY J2 - EXPERT OPIN DRUG DIS VL - 15 PY - 2020 IS - 1 SP - 117 EP - 129 PG - 13 SN - 1746-0441 DO - 10.1080/17460441.2020.1691166 UR - https://m2.mtmt.hu/api/publication/31021220 ID - 31021220 N1 - WoS:hiba:000498746600001 2020-08-26 07:57 év nem egyezik AB - Introduction: The enthalpic and entropic components of the ligand-protein binding free energy reflect the type and quality of the interactions and relate to the physicochemical properties of the ligands. These findings have significance in medicinal chemistry optimizations since they suggest that the thermodynamic profiling of the binding may help monitor and control the unfavorable size and hydrophobicity increase typically accompanying affinity improvements and leading to suboptimal pharmacokinetic properties. Areas covered: This review describes the ligand-protein binding event in terms of elementary steps, their associated interactions, and their enthalpic and entropic consequences. The relationships among the breaking and forming interactions, the binding thermodynamic profile, and the physicochemical properties of the ligands are also discussed. Expert opinion: Analysis of the size dependence of available affinity and favorable enthalpy highlights the limitation of the simultaneous optimization of these quantities. Indeed, moderate, rather than very high affinities can be conciliated with favorable physicochemical and pharmacokinetic profiles as it is supported by the affinity range of historical oral drugs. Although thermodynamic quantities are not suitable endpoints for medicinal chemistry optimizations owing to the complexity of the binding thermodynamics, thermodynamic profiling together with structural studies can be advantageously used to understand the details of the binding process and to optimize it. LA - English DB - MTMT ER - TY - JOUR AU - Jójárt, Balázs AU - Orgován, Zoltán AU - Márki, Árpád AU - Pándy-Szekeres, Gáspár AU - Ferenczy, György AU - Keserű, György Miklós TI - Allosteric activation of metabotropic glutamate receptor 5 JF - JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS J2 - J BIOMOL STRUCT DYN VL - 38 PY - 2020 IS - 9 SP - 2624 EP - 2632 PG - 10 SN - 0739-1102 DO - 10.1080/07391102.2019.1638302 UR - https://m2.mtmt.hu/api/publication/30834454 ID - 30834454 LA - English DB - MTMT ER - TY - JOUR AU - Mihalovits, Levente Márk AU - Ferenczy, György AU - Keserű, György Miklós TI - Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations JF - JOURNAL OF CHEMICAL INFORMATION AND MODELING J2 - J CHEM INF MODEL VL - 60 PY - 2020 IS - 12 SP - 6579 EP - 6594 PG - 16 SN - 1549-9596 DO - 10.1021/acs.jcim.0c00834 UR - https://m2.mtmt.hu/api/publication/31799316 ID - 31799316 LA - English DB - MTMT ER - TY - JOUR AU - Scarpino, Andrea AU - Ferenczy, György AU - Keserű, György Miklós TI - Covalent Docking in Drug Discovery: Scope and Limitations JF - CURRENT PHARMACEUTICAL DESIGN J2 - CURR PHARM DESIGN VL - 26 PY - 2020 IS - 44 SP - 5684 EP - 5699 PG - 16 SN - 1381-6128 DO - 10.2174/1381612824999201105164942 UR - https://m2.mtmt.hu/api/publication/31817108 ID - 31817108 LA - English DB - MTMT ER - TY - JOUR AU - Christopher, John A. AU - Orgován, Zoltán AU - Congreve, Miles AU - Doré, Andrew S. AU - Errey, James C. AU - Marshall, Fiona H. AU - Mason, Jonathan S. AU - Okrasa, Krzysztof AU - Rucktooa, Prakash AU - Serrano-Vega, Maria J. AU - Ferenczy, György AU - Keserű, György Miklós TI - Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu 5 ) X-ray Structures JF - JOURNAL OF MEDICINAL CHEMISTRY J2 - J MED CHEM VL - 62 PY - 2019 IS - 1 SP - 207 EP - 222 PG - 16 SN - 0022-2623 DO - 10.1021/acs.jmedchem.7b01722 UR - https://m2.mtmt.hu/api/publication/30334026 ID - 30334026 LA - English DB - MTMT ER -